EIF3A and non-small cell lung carcinoma: Minor T-carrier of eIF3a Arg803Lys C > T polymorphism have better tolerance than C-carrier to cisplatin-induced toxicity in NSCLC patients (moderate = 42, 14.89% vs. severe = 34, 12.06%; P = 0.01) overall OR cisplatin + carboplatin for T-carrier (T alelle) = 0.54 (95% CI 0.32–0.93, P = 0.03)